Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. (RLAY) on September 12, 2022. The filing reports the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 11,320,755 shares of Common Stock.
- Offering Price: $26.50 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,698,113 shares.
- Estimated Net Proceeds: Approximately $284.5 million (excluding the over-allotment option), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Cowen and Company, LLC.
- Expected Closing Date: September 15, 2022.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the company's operations. It focuses solely on the capital raise transaction.
Material Changes
The primary material change is the execution of the Underwriting Agreement to raise capital. The filing does not present comparative financial performance data against prior periods.
Outlook, Risks, and Contingencies
- Forward-Looking Statements: The filing contains forward-looking statements regarding the anticipated closing of the Offering, which are subject to risks and uncertainties.
- Risk Factors: Actual events may differ materially due to market conditions and the potential failure to complete the Offering on anticipated terms. Detailed risks are referenced in the Company's Form 10-K for the year ended December 31, 2021, and Form 10-Q for the quarter ended June 30, 2022.
- Contingencies: The closing of the Offering is subject to customary closing conditions.
Key Facts for Investor Verification
- Verify the final closing of the Offering and whether the underwriters exercised the over-allotment option.
- Confirm the actual net proceeds received after all expenses are finalized.
- Review the Company's most recent Form 10-Q and Form 10-K for operational financial metrics not included in this 8-K.
- Monitor the use of proceeds as disclosed in the prospectus supplement dated September 12, 2022.